Literature DB >> 18541723

PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway.

Arántzazu Alfranca1, Juan Manuel López-Oliva, Laura Genís, Dolores López-Maderuelo, Isabel Mirones, Dolores Salvado, Antonio J Quesada, Alicia G Arroyo, Juan Miguel Redondo.   

Abstract

The development of a new vascular network is essential for the onset and progression of many pathophysiologic processes. Cyclooxygenase-2 displays a proangiogenic activity in in vitro and in vivo models, mediated principally through its metabolite prostaglandin E(2) (PGE(2)). Here, we provide evidence for a novel signaling route through which PGE(2) activates the Alk5-Smad3 pathway in endothelial cells. PGE(2) induces Alk5-dependent Smad3 nuclear translocation and DNA binding, and the activation of this pathway involves the release of active TGFbeta from its latent form through a process mediated by the metalloproteinase MT1-MMP, whose membrane clustering is promoted by PGE(2). MT1-MMP-dependent transforming growth factor beta (TGFbeta) signaling through Alk5 is also required for PGE(2)-induced endothelial cord formation in vitro, and Alk5 kinase activity is required for PGE(2)-induced neovascularization in vivo. These findings identify a novel signaling pathway linking PGE(2) and TGFbeta, 2 effectors involved in tumor growth and angiogenesis, and reveal potential targets for the treatment of angiogenesis-related disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541723     DOI: 10.1182/blood-2007-09-112268

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.

Authors:  Sonia Alcolea; Rosa Antón; Mercedes Camacho; Marta Soler; Arantzazu Alfranca; Francesc-Xavier Avilés-Jurado; Juan-Miguel Redondo; Miquel Quer; Xavier León; Luis Vila
Journal:  J Lipid Res       Date:  2012-02-04       Impact factor: 5.922

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 3.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 4.  Extracellular matrix, inflammation, and the angiogenic response.

Authors:  Alicia G Arroyo; M Luisa Iruela-Arispe
Journal:  Cardiovasc Res       Date:  2010-02-12       Impact factor: 10.787

Review 5.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

6.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

Review 7.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

8.  The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway.

Authors:  Asmaa Sina; Sébastien Proulx-Bonneau; Alain Roy; Laurent Poliquin; Jian Cao; Borhane Annabi
Journal:  J Cell Commun Signal       Date:  2010-01-27       Impact factor: 5.782

Review 9.  Membrane-associated matrix proteolysis and heart failure.

Authors:  Francis G Spinale; Joseph S Janicki; Michael R Zile
Journal:  Circ Res       Date:  2013-01-04       Impact factor: 17.367

Review 10.  Fluid shear stress-induced osteoarthritis: roles of cyclooxygenase-2 and its metabolic products in inducing the expression of proinflammatory cytokines and matrix metalloproteinases.

Authors:  Pu Wang; Pei-Pei Guan; Chuang Guo; Fei Zhu; Konstantinos Konstantopoulos; Zhan-You Wang
Journal:  FASEB J       Date:  2013-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.